PERRY MATTHEW D 4
4 · CTI BIOPHARMA CORP · Filed Mar 12, 2021
Insider Transaction Report
Form 4
PERRY MATTHEW D
DirectorOther
Transactions
- Award
Stock Option (right to buy)
2021-03-10+80,000→ 80,000 totalExercise: $3.30Exp: 2031-03-10→ Common Stock (80,000 underlying)
Footnotes (2)
- [F1]This stock option was granted on March 10, 2021 and vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2022 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. The stock option is subject to stockholder approval of an increase in the share reserve under the Company's 2017 Equity Incentive Plan, which approval must occur within one year from the grant date.
- [F2]The reporting person is a member of BVF Partners L.P. ("BVF") and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.